17-HDHA
Based on 1 Customer Validation
17-HDHA is a DHA-derived specialized pro-resolving mediator (SPM). 17-HDHA inhibits NF-κB activation by activating PPARγ and upregulating IκBα, targets FPR2 and Bcl-6, and also acts as a precursor of RvD1 and PD1. 17-HDHA inhibits pulmonary artery smooth muscle cell proliferation, regulates the expression of adiponectin, GLUT-4 and inflammatory cytokines, suppresses IgE production by B cells and promotes antibody secretion. 17-HDHA reduces adipose tissue inflammation, improves insulin sensitivity and glucose tolerance, alleviates pathological processes associated with pulmonary hypertension, and enhances antibody responses and virus neutralizing activity against influenza HA. 17-HDHA can be used in research related to obesity-associated inflammation, insulin resistance, glucose intolerance, pulmonary hypertension and influenza virus infection.
For research use only. We do not sell to patients.
- Purity : 98.86%
- CAS No.: 90780-52-2
- Formula: C22H32O3
- Molecular Weight:344.49
-
Storage:
Solution, -20°C, 2 years
All Endogenous Metabolite Isoforms
More
Biological Activity
Description
IC50 & Target
[1]|
PPARγ |
In Vitro
17-HDHA (10-20 nM) potently inhibits PDGFbb-induced proliferation of mouse pulmonary artery smooth muscle cells[2].
17-HDHA inhibits the adhesion and migration of neutrophils to monocytes/macrophages by activating formyl peptide receptor 2 (FPR2)[2].
17-HDHA (10 nM; 24 h) activates PPARγ nuclear translocation and inhibits PDGFbb-stimulated Stat3 phosphorylation in mouse pulmonary artery smooth muscle cells[2].
17-HDHA (10-100 nM; 6 days) significantly reduces spontaneous and stimulus-induced IgE production in peripheral blood mononuclear cells from asthmatic patients not receiving oral corticosteroids[3].
Pretreatment with Dexamethasone (HY-14648) blocks the inhibitory effect of 17-HDHA (10-100 nM; 6 days) on IgE production in peripheral blood mononuclear cells from asthmatic patients not receiving oral corticosteroids[3].
17-HDHA (10-100 nM; 24-72 h) reduces IgE production, ε germline transcript levels and mature IgE mRNA levels in purified CD19+ B cells from healthy donors, and pretreatment with Dexamethasone blocks these inhibitory effects[3].
The ability of 17-HDHA (10-100 nM; 7 days) to reduce IgE production in purified CD19+ B cells and peripheral blood mononuclear cells from healthy donors is blocked by the 5-lipoxygenase inhibitory effect of zileuton[3].
17-HDHA (10-100 nM; 6 days) enhances Dexamethasone-induced PPARγ binding activity in purified CD19+ B cells from healthy donors, but exerts no effect on PPARγ binding activity when used alone[3].
17-HDHA (10-100 nM; 4 h) enhances the expression of Bcl-6 protein in purified CD19+ B cells derived from healthy donors, and pretreatment with Dexamethasone reduces Bcl-6 expression regardless of 17-HDHA treatment[3].
17-HDHA (10-100 nM; administered daily for 6 consecutive days, with 30 min pre-incubation prior to stimulation) upregulates the expression of CD80 and CD86 on purified naive CD19+ B cells from C57BL/6 mice activated by CpG combined with anti-IgM, without altering the expression of MHC class II[4].
17-HDHA (10-100 nM; administered daily for 6 consecutive days, with 30 min pre-incubation prior to stimulation) enhances the production of IgM and IgG in purified naive CD19+ B cells from C57BL/6 mice activated by CpG combined with anti-IgM, and upregulates the mRNA and protein levels of Blimp-1[4].
17-HDHA (10-100 nM; 4 h) enhances the binding of Bcl-6 to the promoter region of εGLT in peripheral blood mononuclear cells from healthy donors, while pretreatment with Dexamethasone blocks this enhancing effect[3].
17-HDHA (10-100 nM; administered daily for 5-6 days, with 30 min pre-incubation prior to stimulation) promotes the differentiation of naive CD19+CD138− B cells from plasma cell-depleted C57BL/6 mice into IgM− secreting cells, IgG-secreting cells and plasmablasts, increases IL-10 production, and exerts no effect on cell proliferation or the production of IL-6/TNF-α[4].
17-HDHA (0.4-50 μM; 48 h during viral infection) does not inhibit the replication of pH1N1/E3 influenza virus in MDCK cells at the highest concentration[4].
17-HDHA (5-25 μM; 10 min) inhibits collagen-induced aggregation of washed human platelets at a concentration of 5 μM, inhibits thrombin-induced aggregation of washed human platelets at a concentration of 25 μM, and exhibits no agonist activity[5].
17-HDHA (300-1000 nM; 4-24 h) induces elevated levels of specific D-series resolvins and 10S,17S-dihydroxydocosahexaenoic acid (10S,17S-diHDHA) in human primary great saphenous vein endothelial cells (ECs) and vascular smooth muscle cells (VSMCs). Moreover, starting from treatment with 300 nM 17-HDHA, the production of RvD1 shows concentration- and time-dependent patterns[6].
17-HDHA (1 μM; 24 h) increases 5-LOX protein expression by 94% in primary human great saphenous vein endothelial cells (but not in vascular smooth muscle cells)[6].
17-HDHA (1 μM; 5 h) induces the translocation of 5-LOX from the nucleus to the cytoplasm in primary human great saphenous vein endothelial cells (ECs) and vascular smooth muscle cells (VSMCs), with the relative cytoplasmic 5-LOX expression levels increasing by 28% and 37% in ECs and VSMCs, respectively[6].
Conditioned medium generated from human primary great saphenous vein endothelial cells (ECs) treated with 17-HDHA (1 μM; 24 h) attenuates the adhesion of TNF-α-stimulated U937 monocytes to ECs, and this effect is partially mediated by RvD1 signaling via ALX/FPR2 and GPR32 receptors[6].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:mouse pulmonary artery smooth muscle cells (PASMCs)
-
Concentration:10 nM
-
Incubation Time:24 h
-
Result:Promoted PPARγ nuclear translocation in PDGFbb-stimulated mouse PASMCs, reversing the PDGFbb-induced reduction in nuclear PPARγ.
Suppressed PDGFbb-induced Stat3 phosphorylation in these cells.
-
Cell Line:PBMCs from asthma patients; B cells from healthy donors
-
Concentration:10 and 100 nM
-
Incubation Time:6 days
-
Result:Significantly reduced spontaneous and induced IgE production; dexamethasone pretreatment blocked this effect.
-
Cell Line:B cells from healthy donors
-
Concentration:10 and 100 nM
-
Incubation Time:1 day (εGLT) or 3 days (mature IgE mRNA)
-
Result:Decreased εGLT and mature IgE mRNA levels; dexamethasone pretreatment blocked this effect.
-
Cell Line:B cells from healthy donors
-
Concentration:10 and 100 nM
-
Incubation Time:4 h
-
Result:Increased Bcl-6 protein expression in a concentration-dependent manner; dexamethasone pretreatment reduced basal Bcl-6 expression and blocked this effect.
-
Cell Line:Mouse B cells (CD19⁺)
-
Concentration:10 and 100 nM
-
Incubation Time:6 days
-
Result:Increased IgM and IgG production in a concentration-dependent manner, with a ~2-fold increase at 100 nM.
-
Cell Line:Endothelial cells and vascular smooth muscle cells
-
Concentration:1 μM
-
Incubation Time:5 h
-
Result:Induced translocation of 5-LOX from nucleus to cytoplasm, with a ~28% (ECs) and ~37% (VSMCs) increase in cytoplasmic/nuclear fluorescence ratio.
-
Cell Line:Human ECs and VSMCs
-
Concentration:300, 500 and 1000 nM
-
Incubation Time:4, 8 and 24 h
-
Result:Concentration- and time-dependently increased RvD1 production, with significant increases at 300 nM and peak at 8 h.
In Vivo
Endogenous 17-HDHA, produced by eosinophils via arachidonic acid 15-lipoxygenase, inhibits pulmonary hypertension-related pathological changes induced by Sugen/hypoxia in mice[2].
17-HDHA (1 μg; i.p.; single synchronized injection) enhances antigen-specific IgM and IgG production in OVA-immunized mice, with significantly increased titers detected at key time points after immunization[4].
17-HDHA (1 μg; intramuscular injection; administered concurrently with primary and booster immunizations) enhances the production of HA-specific IgG in mice immunized with HA combined with CpG ODN, with significantly elevated antibody titers detected at multiple time points post-immunization[4].
17-HDHA (1 μg; intramuscular injection; administered concurrently with each immunization during weeks 0-4) enhances the production of HA-specific antibodies and the differentiation of plasma cells in the bone marrow of mice immunized with HA alone, significantly increasing IgG titers and the frequency of antibody-secreting cells[4].
17-HDHA (1 μg; intramuscular injection; administered concurrently with each immunization during weeks 0-4) enhances the protective efficacy of influenza HA vaccine in mice, enabling detectable neutralizing antibodies, minimal body weight loss, and 100% survival rate in mice following live influenza virus challenge[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6J (male, wild-type, diet-induced obesity via 60% kcal high-fat diet for 17 weeks)[1]
-
Dosage:50 ng/g body weight
-
Administration:i.p.; every 12 h; 8 days; osmotic pump; continuous; 15 days
-
Result:Reduced mRNA expression of inflammatory genes (MCP-1, TNF-α, IL-6, OPN, NF-κB) in gonadal adipose tissue.
Increased IκBα protein level in gonadal adipose tissue.
Reduced CD11c+/CD206+ adipose tissue macrophage ratio.
Enhanced mRNA expression of PPARγ, PPARα, GLUT-4, and adiponectin in gonadal adipose tissue.
Moderately improved glucose tolerance with reduced plasma insulin at 45 minutes post-glucose challenge.
Achieved 30% reduction in fasting insulin concentration and 40% lower HOMA-IR (non-significant trends).
Showed trend toward improved insulin tolerance at 60, 90, and 120 minutes post-insulin injection.
Significantly decreased fasting insulin concentration and HOMA-IR.
Showed trend toward reduced blood glucose at 30 minutes post-insulin injection.
Significantly lowered blood glucose at 15 minutes post-glucose challenge.
Reduced plasma insulin levels at baseline and 45 minutes post-glucose challenge.
-
Animal Model:C57BL/6J (male, 8-10 wk old) were immunized via intraperitoneal injection with OVA protein (10 μg/mouse) emulsified in complete Freund's adjuvant (CFA). Immediately after the primary immunization, the compound was administered via intraperitoneal injection at the same site. Blood samples were collected at 2 and 6 weeks after the primary immunization to measure OVA-specific IgM and IgG antibody levels. At week 10, mice received a booster immunization via intraperitoneal injection with OVA (10 μg/mouse) in PBS. Blood samples were collected again at 2 weeks after the booster immunization for antibody detection
[4] -
Dosage:1 μg
-
Administration:i.p.; single concurrent injection
-
Result:Showed significantly higher OVA-specific IgM titers at weeks 6 and 12 compared with vehicle controls.
Showed significantly higher OVA-specific IgG titers at week 6 compared with vehicle controls.
Showed a decreasing trend in OVA-specific IgE levels compared with vehicle controls.
-
Animal Model:C57BL/6J (male, 8-10 wk old) were primed via intramuscular injection at week 0 with recombinant HA protein (H1N1 A/Brisbane/59/2007 (HY-P74094), 5 μg/mouse), CpG ODN 1826 (HY-146245) (10 μg/mouse), and the compound (1 μg/mouse). Booster immunizations were given at weeks 2 and 4 in the same manner. [4]
-
Dosage:1 μg
-
Administration:i.m.; concurrent with primary and booster immunizations
-
Result:Showed significantly higher HA-specific IgG titers at weeks 3, 6, and 11 compared with vehicle controls.
Showed no significant differences in HA-specific IgM titers at any time point compared with vehicle controls.
-
Animal Model:C57BL/6J (male, 8-10 wk old) were immunized via intramuscular injection at weeks 0, 2, and 4 with recombinant HA protein (H1N1 A/California/04/2009, 2 μg/mouse) and the compound (1 μg/mouse)[4]
-
Dosage:1 μg
-
Administration:i.m.; concurrent with each immunization at weeks 0, 2, and 4
-
Result:Showed a 2-fold increase in HA-specific IgM titers at week 2 compared with mock and vehicle controls.
Showed a 9-fold increase in HA-specific IgG titers at week 2 compared with mock and vehicle controls.
Showed a 3-fold increase in HA-specific IgG titers at week 4 compared with vehicle controls.
Showed a 9-fold increase in HA-specific IgG titers at week 6 compared with vehicle controls.
Showed a 2-fold increase in the percentage of CD19+ CD138+ plasma cells in the bone marrow compared with mock and vehicle controls.
Showed a 2-fold increase in HA-specific IgG-secreting bone marrow cells compared with mock and vehicle controls.
Showed no differences in splenic CD19+ CD138+ plasma cells compared with controls.
-
Animal Model:C57BL/6J (male, 8-10 wk old) were immunized via intramuscular injection at weeks 0, 2, and 4 with recombinant HA protein (H1N1 A/California/04/2009, 2 μg/mouse) and 17-HDHA (1 μg/mouse) or vehicle control (3 immunizations in total). Blood was collected at 14 days after the last immunization (week 6), and serum neutralizing antibody titers were measured by GFP-based microneutralization assay. At 28 days after the last immunization (week 8), mice were challenged intranasally with 300 PFU/mouse of mouse-adapted live influenza virus H1N1 A/California/04/E3/2009[4]
-
Dosage:1 μg
-
Administration:i.m.; concurrent with each immunization at weeks 0, 2, and 4
-
Result:Showed 44% of treated mice with detectable neutralizing antibody titers (≥40) at week 6, compared with 0% of mock and vehicle controls.
Showed minimal weight loss following viral infection, while mock and vehicle-treated mice experienced dramatic weight loss.
Showed a 100% survival rate following viral infection, compared with 30% for mock controls and 80% for vehicle controls.
Chemical Information
-
CAS No. 90780-52-2
-
Appearance Liquid
-
Molecular Weight 344.49
-
Formula C22H32O3
-
Color Colorless to light yellow
-
SMILES
CC/C=C\CC(O)/C=C/C=C\C/C=C\C/C=C\C/C=C\CCC(O)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Solution, -20°C, 2 years
Protocols
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Somatic Cell Culture
A method of simulating the in vivo environment in vitro to maintain the cell growth, differentation and main functions.
-
CFSE Dye Dilution Proliferation Assay
The CFSE (carboxyfluorescein diacetate succinimidyl ester) dye dilution proliferation assay is based on the covalent labeling of intracellular proteins by a cell-permeant fluorescent dye that becomes fluorescent upon intracellular ester cleavage and then is stably retained within cells. As labeled cells divide, the dye is partitioned equally between daughter cells, resulting in a stepwise halving of fluorescence intensity that can be quantified by flow cytometry to determine the number of cell divisions undergone by each cell population. This fluorescence dilution approach enables quantitative tracking of lymphocyte proliferation at the single-cell level over multiple rounds of division. CFSE-based proliferation analysis has been widely applied to measure antigen-driven lymphocyte expansion in vitro, where discrete fluorescence peaks correspond to successive cell divisions and allow reconstruction of proliferative history within heterogeneous populations.
-
Dye-dilution cell tracking and proliferation staining
Dye-dilution cell tracking assays quantify cell proliferation by covalently labeling intracellular proteins with a stable fluorescent dye that is equally partitioned between daughter cells during mitosis, resulting in stepwise halving of fluorescence intensity with each cell division as measured by flow cytometry histograms. Carboxyfluorescein diacetate succinimidyl ester (CFSE) is a prototypical dye that diffuses into cells, is enzymatically converted into a fluorescent compound, and then covalently binds intracellular amine groups, producing long-lived fluorescence suitable for tracking multiple rounds of division in vitro and in vivo. Successive generations of dividing cells form discrete peaks of decreasing fluorescence intensity, enabling estimation of proliferation history, precursor frequency, and division index within heterogeneous populations. Alternative dyes such as CellTrace Violet (CTV) and far-red membrane dyes (e. g. , PKH26) follow the same dilution principle but differ
-
CCK-8/WST-8 Cell Proliferation Assay
The CCK-8/WST-8 assay is based on the reduction of the water-soluble tetrazolium salt WST-8 to a water-soluble formazan product by cellular dehydrogenases in metabolically active cells, where the generated formazan amount is proportional to the number of living cells and is quantified by measuring absorbance in the visible range, providing a colorimetric readout for cell viability and proliferation assessment. This class of tetrazolium-based assays improves upon earlier MTT-based systems by producing a water-soluble formazan, eliminating the need for organic solubilization steps and enabling direct spectrophotometric measurement in culture medium.
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Cell Counting-Based Growth Curve Assay
Cell counting-based growth curve assays quantify cell proliferation by directly measuring changes in viable cell number over time using manual or automated counting methods such as hemocytometer-based counting or instrument-assisted cell enumeration, enabling construction of growth curves that reflect population expansion dynamics in response to culture conditions. A widely used approach is trypan blue exclusion with hemocytometer counting, where membrane-compromised (non-viable) cells take up the dye, allowing discrimination between viable and non-viable cells while simultaneously enabling total cell number quantification. Repeated sampling across time points allows estimation of proliferation rate, growth phases, and comparative growth kinetics between experimental conditions.
-
Colony Formation (Clonogenic) Assay
The clonogenic (colony formation) assay measures the ability of a single cell to retain reproductive viability and form a macroscopic colony, typically defined as a cluster derived from one progenitor cell after a defined growth period. This assay is widely used to evaluate cell survival after exposure to ionizing radiation or cytotoxic treatments and is considered a standard method in radiation biology for generating dose-response relationships of reproductive cell death. Colony formation reflects long-term proliferative capacity rather than short-term metabolic activity, and survival is quantified by comparing treated versus untreated conditions based on colony number and derived survival fractions.
-
Research Protocol for Metabolic Diseases
AMP-activated protein kinase, AMPK, is a conserved cellular energy sensor that responds to reduced cellular energy status and coordinates metabolism by increasing ATP-generating catabolic pathways while suppressing ATP-consuming anabolic processes. In metabolic disease research, the AMPK pathway is experimentally relevant because it regulates hepatic lipid synthesis, fatty acid oxidation, glucose production, skeletal-muscle glucose disposal, mTORC1-linked biosynthesis, autophagy, mitochondrial homeostasis, and whole-body energy balance. The central pathway logic is that energy stress, metformin, exercise-like stimulation, or direct AMPK activators increase AMPKα Thr172 phosphorylation and downstream substrate phosphorylation, including ACC and RAPTOR. Phosphorylation of ACC suppresses lipogenesis and supports fatty acid oxidation, whereas phosphorylation of RAPTOR suppresses mTORC1 signaling and links cellular energy status to growth and protein synthesis control. The pathway is linked
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
-
EdU Incorporation Assay (Click Chemistry-Based DNA Synthesis Measurement)
The EdU incorporation assay measures DNA synthesis by adding the thymidine analog 5-ethynyl-2′-deoxyuridine to cells or tissues, where it is incorporated into newly synthesized DNA during S phase. Incorporated EdU is detected by copper-catalyzed azide-alkyne cycloaddition, in which a fluorescent azide covalently reacts with the ethynyl group on EdU, allowing S-phase cells to be detected by fluorescence microscopy, flow cytometry, or high-content imaging. EdU detection does not require DNA denaturation or anti-BrdU antibody access, which preserves sample structure and improves compatibility with immunostaining and multiparameter cytometry compared with BrdU-based detection. EdU can be cytotoxic in a cell-type- and exposure-dependent manner, so pulse duration, concentration, and continuous-labeling designs should be validated for each cell type.
-
Ki-67 Immunostaining Proliferation Assay
Ki-67 immunostaining measures the growth fraction of a cell population by detecting Ki-67, a nuclear antigen present in proliferating cells and absent in quiescent G0 cells. The readout is the percentage of Ki-67-positive nuclei among total counted cells, commonly called the Ki-67 labeling index or proliferation index.
-
PCNA Immunodetection Proliferation Assay
PCNA immunodetection measures proliferative activity by detecting proliferating cell nuclear antigen, a nuclear protein associated with DNA polymerase δ function and DNA replication. The assay readout is the proportion of PCNA-positive nuclei among total counted cells, but PCNA labeling is not identical to BrdU labeling because PCNA can mark late G1/early S-associated replication competence and may persist beyond active DNA synthesis depending on fixation and extraction conditions.
-
LPS-Induced Endotoxemia/Systemic Inflammation
Lipopolysaccharide (LPS)-induced endotoxemia is a widely used in vivo model of acute systemic inflammation in which LPS, a Gram-negative bacterial endotoxin, activates innate immune signaling primarily through TLR4, leading to rapid and transient induction of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-1β in circulation and tissues. This cytokine surge is commonly used as a measurable readout of systemic inflammatory activation and immune dysregulation, and is typically assessed within hours after intraperitoneal LPS administration in mouse models of endotoxemia. The model captures key features of systemic inflammatory response syndrome, including cytokine release, immune cell activation, and downstream tissue responses, and has been used to evaluate anti-inflammatory interventions such as cytokine modulation, lipid mediators, and immune cell-targeting therapies.
-
Protocol for Cell Counting and Cell Density Analysis
Cell counting and cell-density analysis estimate the number of cells in a known volume or field area. Manual hemocytometer counting uses a chamber of defined geometry to convert counted cells into cells/mL, while automated counters and image-analysis workflows detect cell objects from optical, brightfield, fluorescence, impedance, or digital-image features. Trypan blue viability counting is based on dye exclusion: viable cells with intact membranes exclude dye, while non-viable cells with compromised membranes stain blue. The readout is total cell density, viable-cell density, dead-cell density, and percent viability. Cell density can also be estimated from microscopy images by counting objects per image area, from flow cytometry using calibrated volume or reference particles, or from in situ microscopy in bioreactors after calibration against reference methods such as hemocytometer or flow cytometry.
-
Large-size fat particle sorting
Large-size fat particle sorting is widely used to isolate cells up to 200 μm in diameter. Single-cell flow sorting will allow greater insight into adipocyte heterogeneity by identifying gene expression, protein composition, and metabolic signatures at the single-cell level.
-
Research Protocol for Endocrine Diseases
Endocrine diseases often arise from disrupted hormone production, hormone signaling, or target-tissue responsiveness; for diabetes-focused endocrine disease models, insulin signaling regulates glucose uptake, hepatic glucose output, lipid metabolism, and β-cell compensation. Type 2 diabetes develops through interacting defects in insulin resistance, β-cell dysfunction, adipose inflammation, hepatic glucose overproduction, altered incretin signaling, and ectopic lipid metabolism. A major unresolved question is whether endocrine dysfunction is driven primarily by target-tissue insulin resistance, intrinsic β-cell failure, immune/inflammatory stress, or combined multi-organ failure that differs by disease stage.
-
MTT Cell Proliferation Assay
The MTT assay is a colorimetric endpoint assay for estimating viable cell number, cell growth, cytotoxicity, or cell activation in cultured mammalian cells. Living cells reduce the yellow tetrazolium salt MTT into purple/blue formazan, while dead cells do not generate the same signal; the resulting color can be quantified with a multiwell spectrophotometer. MTT reduction is commonly interpreted as a readout of metabolic activity that often correlates with viable cell number, but it should not be treated as a direct cell-counting method unless the assay is optimized for the cell type and experimental condition. Studies show that MTT reduction can involve mitochondrial and non-mitochondrial reducing systems, and formazan may accumulate in intracellular lipid droplets rather than simply marking mitochondria.
Purity & Documentation
-
Data Sheet (291 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Neuhofer A, et al. Impaired local production of proresolving lipid mediators in obesity and 17-HDHA as a potential treatment for obesity-associated inflammation. Diabetes. 2013 Jun;62(6):1945-56. [Content Brief]
[2]. Shu T, et al. Eosinophils protect against pulmonary hypertension through 14-HDHA and 17-HDHA. The European respiratory journal. 2023 Mar;61(3):2200582. [Content Brief]
[3]. Kim N, et al. Corticosteroids inhibit anti-IgE activities of specialized proresolving mediators on B cells from asthma patients. JCI insight. 2017 Feb 09;2(3):e88588. [Content Brief]
[4]. Ramon S, et al. The specialized proresolving mediator 17-HDHA enhances the antibody-mediated immune response against influenza virus: a new class of adjuvant?. Journal of immunology (Baltimore, Md. : 1950). 2014 Dec 15;193(12):6031-40. [Content Brief]
[5]. Tran M, et al. Investigating the catalytic efficiency of C22-Fatty acids with LOX human isozymes and the platelet response of the C22-oxylipin products. Archives of biochemistry and biophysics. 2023 Oct 01;747:109742. [Content Brief]
[6]. Chatterjee A, et al. Biosynthesis of proresolving lipid mediators by vascular cells and tissues. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2017 Aug;31(8):3393-3402. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)